This section is The content in this section is supplied by GlobeNewswire for the purposes of distributing press releases on behalf of its clients. Postmedia has not reviewed the content. by GlobeNewswire Article content
Recommendation is an important step toward potential public reimbursement for eligible adults whose chronic hypoparathyroidism is not adequately controlled with conventional therapy
Sign In or Create an Account
or View more offersArticle content
MONTREAL, Sept. 03, 2026 (GLOBE NEWSWIRE) — Pendopharm, a division of Pharmascience Inc., in collaboration with Ascendis Pharma A/S, today announced that Canada’s Drug Agency, or CDA-AMC, has recommended that Yorvipath® (palopegteriparatide injection) be reimbursed with conditions by participating public drug plans for eligible adults with chronic hypoparathyroidism that are not adequately controlled with conventional therapy.
Article contentWe apologize, but this video has failed to load.Try refreshing your browser, or
tap here to see other videos from our team.Article content
Story continues below
This advertisement has not loaded yet, but your article continues below.
Article content
Yorvipath® (palopegteriparatide injection) is a parathyroid hormone (PTH) replacement therapy for the treatment of chronic hypoparathyroidism in adults, authorized by Health Canada on January 28, 2026. The CDA-AMC recommendation represents an important step in the Canadian public reimbursement process. The CDA-AMC review considered evidence from the Phase 3 PaTHway clinical trial, which evaluated palopegteriparatide in adults with chronic hypoparathyroidism.
Article contentArticle content
Participating federal, provincial, and territorial drug plans will make their own final listing decisions.
Article content
“This recommendation is an important milestone for adults whose chronic hypoparathyroidism remains inadequately controlled despite conventional therapy,” said Jad Isber, Vice-President and General Manager, Pendopharm. “We welcome CDA-AMC’s recognition of the needs of eligible adults with chronic hypoparathyroidism and will continue to work through the Canadian reimbursement process.”
Article content
“People living with chronic hypoparathyroidism can face significant daily challenges even while taking intensive calcium and active vitamin D therapy,” said Dr. Aliya Khan, Clinical Professor of Medicine, and Director of the Calcium Disorders Clinic, McMaster University, Hamilton, Ontario. “Conventional therapy generally consists of oral calcium and active vitamin D. Guidelines suggest conventional therapy as first-line; PTH therapy may be considered when conventional therapy is unsatisfactory. For appropriate adults, a PTH replacement therapy may offer a different treatment approach by addressing the underlying hormone deficiency. This recommendation is an important development for appropriate patients whose disease remains inadequately controlled with conventional therapy.”
Article content
Story continues below
This advertisement has not loaded yet, but your article continues below.
Article content
“This recommendation is meaningful for our community because it recognizes the challenges experienced by some people living with chronic hypoparathyroidism and the need for access discussions for eligible patients,” said Patty Keating, Executive Director, HypoPARAthyroidism Association (USA).
Article content
For more information about the product, such as contraindications, precautions, adverse effects, drug interactions, dosage and clinical usage conditions, please consult the Product Monograph at https://pdf.hres.ca/dpd_pm/00083317.PDF. This document is also available through our medical department at [email protected] or by calling us at +1 (888) 550-6060.
Article content
We encourage patients to consult their doctor for more information to ensure this treatment right choice for them. Always read and follow the label. This product may not be right for you.
Article content
YORVIPATH is a registered trademark of Ascendis Pharma Bone Diseases A/S, used under license.
Article content
About Pendopharm, a division of Pharmascience Inc.
Article content
Pendopharm, the specialty division of Pharmascience Inc., is a leading Canadian pharmaceutical company. Its areas of expertise include gastroenterology, sports medicine and orthopedics, neurology, and cardiology. Pendopharm has extensive experience and strong capabilities to effectively manage its growing product portfolio.